IGF-1R expression predicts clinical outcome in patients with locally advanced oral squamous cell carcinoma

SummaryTo assess the expression of IGF-1R in oral cavity squamous cell carcinoma patients, to explore its relation with clinical and pathologic prognostic factors and its role in predicting clinical outcome. One hundred and thirty-one consecutive patients suffering from oral cavity squamous cell carcinoma were included in this study from July 1989 to April 2005. Follow-up was closed in May 2010. The mean follow-up for survivors was 110.26 ± 47.42 months. Patients were staged following the TNM classification. Patients in tumour stages I and II were referred to surgery. Patients in stages III–IV were referred to postoperative radiotherapy. Radiation therapy was administered up to a mean dose of 62.13 ± 7.74 Gy in 1.8–2 Gy fractions. IGF-1R expression was studied by immunohistochemistry in paraffin-embedded tumour tissue. IGF-1R was expressed in 101 patients (77.1%). IGF-1R expression was related to tumour grade (P = 0.012). Tumour stage was the most important prognostic factor for survival. Low (negative and fairly) IGF-1R tumour expression was correlated to better long-term Local Disease Free Survival (P = 0.016), Disease-Free Survival (P = 0.029), and Survival (P = 0.009) in patients achieving tumour stages III–IV. Low IGF-1R expression was related to better long-term control in patients suffering locally advanced oral carcinoma.